Sex-specific influence of Lipoprotein(a) levels on coronary plaque characteristics: - The COPRODUCTION Registry -
Open Access
- 9 October 2025
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (12) , 1739-1751
Abstract
Background: Elevated Lipoprotein(a) Lp(a) levels are associated with coronary atherosclerosis as detected by cardiac computed tomography angiography (CCTA). However, quantitative data including coronary plaque volumes and characteristics are scarce. The current study evaluated the sex-specific correlations between (Lp(a)) levels and the extent and composition of coronary stenosis and plaques. Methods: 1,946 patients undergoing CCTA (third-generation dual-source scanner) for suspected coronary artery disease were included whose Lp(a) levels were available. Lp(a) values ≥ 125 nmol/L were classified as high. Results: High Lp(a) levels were observed in 336 patients, who had greater maximum degree of stenosis (49.5 ± 26.4% vs. 43.5 ± 27.6%, P = 0.002), mainly as a result of the pronounced difference in males (53.8 ± 26.0% vs. 46.2 ± 26.8%, P = 0.001). A strong correlation between higher Lp(a) values and high-risk plaque features was noted in the overall cohort (odds ratio [OR]: 1.645; 95% confidence interval [CI]: 1.011 to 2.593; P = 0.037), independent of age and LDL-cholesterol values. In males, high Lp(a) levels were associated with greater total plaque volumes (118.1 [IQR 18.3–284.4] vs. 83.2 [IQR 11.8–226.3] mm 3 , P = 0.018, Pint = 0.09), including fibrotic components (27.6 [IQR 2.1–109.9] vs. 18.2 [IQR 0.4–65.0] mm 3 , P = 0.011, Pint = 0.013), whereas in women, only a marginal linear correlation with total plaque volume was observed (19.2 vs. 8.1 mm 3 ; Spearman’s rank correlation R = 0.16, P = 0.037). Conclusions: Our study identifies novel sex-specific correlations between Lp(a) levels and coronary plaque characteristics. High Lp(a) levels in men seems to be associated with increased fibrotic plaque volumes and may contribute to greater total plaque burden and high-risk plaque features. GraphicalKeywords
Funding Information
- Novartis Pharma
- Universitätsklinikum Freiburg
This publication has 29 references indexed in Scilit:
- Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2020
- From Detecting the Vulnerable Plaque to Managing the Vulnerable PatientJACC, 2019
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease OutcomesJAMA Cardiology, 2019
- Coronary CT angiography (CCTA) using third-generation dual-source CT for ruling out in-stent restenosisClinical Research in Cardiology, 2018
- Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering TherapiesJAMA Cardiology, 2018
- Distinct Morphological Features of Ruptured Culprit Plaque for Acute Coronary Events Compared to Those With Silent Rupture and Thin-Cap FibroatheromaJACC, 2014
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Lipoprotein(a) and Apolipoprotein(a) IsoformsCirculation, 2005
- Considerable Time From the Onset of Plaque Rupture and/or Thrombi Until the Onset of Acute Myocardial Infarction in HumansCirculation, 2000